Objective      To observe the clinical efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) on recurrent lymphoma after autologous stem cell transplantation (auto-HSCT).        Methods      A total of 17 patients with recurrent lymphoma after auto-HSCT underwent allo-HSCT in our department from January 2000 to December 2011. There were human leukocyte antigen (HLA) full matched (6/6) in 10 patients

5/6 matched in 5

and 4/6 matched in 2. All patents were treated with standardized co

nditioning regimen consisting of cyclophosphamide 120 mg/kg in 2 d

busulfan 12 to 14 mg/kg in 4 d by oral taking

and fludarabine 30 mg/m

2

for 1 to 5 d. Graft-versus-host disease (GVHD) was prevented by CsA+MTX+MMF for HLA full-matched and ATG +CsA +MTX+MMF for mismatched. Grafts were peripheral blood stem cells and bone marrow.       Results      Hematopoietic reconstitution achieved in all 17 patients. There were 9 cases (52.94%) with acute GVHD

and 11 cases (64.70%) with chronic GVHD. During the follow-up period of 12 to 120 month

6 patients died of disease recurrence after transplantation 8

11

15

19

21

and 34 months respectively

3 died of GVHD with infection

and 8 survived until now.       Conclusion      Allo-HSCT is an effective therapy for recurrent lymphoma after auto-HSCT.